Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 708 results

Media Release / Oct 21, 2014

Novartis teams up with multiple sclerosis advocate and musician David Osmond to launch MS education initiative Our Voice in Song™
Media Release / Oct 20, 2014

Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis

- Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015- FDA Advisory Committee…
Media Release / Oct 20, 2014

Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis
Media Release / Oct 15, 2014

Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)

- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191- Largest…
Media Release / Oct 15, 2014

Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)
Media Release / Sep 27, 2014

Novartis drug Afinitor® is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial

Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1)Pancreatic NET (pNET) affects about 2…
Media Release / Sep 27, 2014

Novartis drug Afinitor® is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial
Media Release / Aug 30, 2014

Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1)- On all-cause mortality, LCZ696 doubled the effect…
Media Release / Aug 30, 2014

Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
Media Release / Aug 11, 2014

Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696

-- LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF-- PARADIGM-HF is the largest heart…

‹ Previous page
1
…
51
52
53
54
55
56
57
…
71
› Next page